Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Shell PLC — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.2 (market cap $9.43B), while Shell PLC trades at $90.24 (market cap $250.44B). The key difference: Shell PLC is far larger — about 26.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Shell PLC pays a 3.45% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SHEL | |
|---|---|---|
Market Cap | $9.43B | $250.44B |
Sector | Health | Energy |
52-Week High | $356.25 | $94.15 |
52-Week Low | $241.71 | $70.31 |
Enterprise Value | $9.18B | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Shell (SHEL) trades at $90.15, up 0.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.60. Recent Q2 2026 earnings beat estimates with EPS of $3.52 versus $3.23 expected, driven by higher oil prices and strong operational performance. The company maintains solid profitability with a net income margin of 8.76% and ROE of 14.35%, while cash flow from operations reached $42.86B in 2025.
Outlook is positive due to undervaluation (P/E of 10.01), rising oil prices, and strategic asset sales, but risks include commodity volatility and geopolitical tensions affecting energy markets. With 69% of analysts rating it Buy and institutional support, SHEL offers growth potential, though investors should monitor debt levels and global energy demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
